Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

被引：2
|
作者：
Poveda, Andres
Lheureux, Stephanie
Colombo, Nicoletta
Cibula, David
Lindemann, Kristina
Weberpals, Johanne I.
Bjurberg, Maria
Oaknin, Ana
Sikorska, Magdalena
Gonzalez Martin, Antonio
Madry, Radoslaw
Jesus Rubio, Maria
Ledermann, Jonathan A.
Davidson, Richard
Blakeley, Christopher
Bennett, James
Brown, Jessica
Skof, Erik
机构：
[1] Initia Oncol, Valencia, Spain
[2] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada
[3] IEO Ist Europeo Oncol, Milan, Italy
[4] Charles Univ Hosp, Fac Med 1, Prague, Czech Republic
[5] Oslo Univ Hosp, Oslo, Norway
[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[7] Lund Univ, Skane Univ Hosp, Lund, Sweden
[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[9] Olsztyn Prov Specialist Hosp, Olsztyn, Poland
[10] Clin Univ Navarra, Madrid, Spain
[11] Lords Med Univ Karol Marcinkowski, Clin Hosp Transfigurat, Poznan, Poland
[12] Hosp Univ Reina Sofia, Dept Med Oncol, Cordoba, Spain
[13] UCL, UCL Canc Inst, London, England
[14] UCL Hosp, London, England
[15] AstraZeneca, Cambridge, England
[16] Inst Oncol Ljubljana, Ljubljana, Slovenia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5545
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
    Poveda, Andres
    Lheureux, Stephanie
    Colombo, Nicoletta
    Cibula, David
    Lindemann, Kristina
    Weberpals, Johanne, I
    Bjurberg, Maria
    Oaknin, Ana
    Sikorska, Magdalena
    Gonzalez Martin, Antonio
    Madry, Radoslaw
    Rubio Perez, Maria Jesus
    Davidson, Richard
    Blakeley, Christopher
    Bennett, James
    Barnicle, Alan
    Skof, Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
    Lindemann, K.
    Skof, E.
    Colombo, N.
    Gonzalez-Martin, A.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S738 - S739
  • [3] Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
    Poveda Velasco, A. M.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Elstrand, M.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez Martin, A. J.
    Madry, R.
    Rubio Perez, M. J.
    Ledermann, J. A.
    Ozgoren, O.
    Barnicle, A.
    Marshall, H.
    Bashir, Z.
    Skof, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S790 - S790
  • [4] OPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)
    Poveda, A. M.
    Davidson, R.
    Blakeley, C.
    Milner, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    Penson, R. T.
    O'Malley, D. M.
    Kim, J-W.
    Zimmermann, S.
    Roxburgh, P.
    Sohn, J.
    Stemmer, S. M.
    Bastian, S.
    Ferguson, M.
    You, B.
    Domchek, S.
    Gao, H.
    Angell, H.
    Meyer, K.
    Opincar, L.
    Ottesen, L.
    Koralek, D. O.
    Banerjee, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S615 - S616
  • [6] EFFICACY AND SAFETY OF MAINTENANCE OLAPARIB BY PATIENT AGE IN NON-GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER IN OPINION
    Skof, E.
    Bjurberg, M.
    Rubio Perez, M. J.
    Davidson, D.
    Blakeley, C.
    Bennett, J.
    Poveda, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A202 - A203
  • [7] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Poveda, A.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Lindemann, K.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez-Martin, A.
    Madry, R.
    Perez, M. J. Rubio
    Ledermann, J.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Skof, E.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
  • [8] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
    Penson, R. T.
    Valencia, R. V.
    Cibula, D.
    Colombo, N.
    Ill, C. L.
    Bidzinski, M.
    Kim, J. W.
    Nam, J. H.
    Madry, R.
    Hernandez, C. H.
    Mora, P.
    Ryu, S. Y.
    Milenkova, T.
    Lowe, E.
    Barker, L.
    Scambia, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
  • [9] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
    Penson, Richard T.
    Valencia, Ricardo Villalobos
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A.
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos Hernandez
    Mora, Paulo Alexandre Ribeiro
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design
    Poveda, Andres M.
    Davidson, Richard
    Blakeley, Christopher
    Milner, Alvin
    FUTURE ONCOLOGY, 2019, 15 (32) : 3651 - 3663
12345